Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approves excimer laser for refractive surgery
The FDA approved Bausch & Lomb's 100 Hz excimer laser (217z100) as part of the company's Zyoptix personalized laser vision-correction system.
The FDA approved Bausch & Lomb’s 100 Hz excimer laser (217z100) as part of the company’s Zyoptix personalized laser vision-correction system.
In both standard and custom treatment modes, the 217z100 laser operates at twice the speed of Bausch & Lomb’s current system on the U.S. market, according to the company.
The laser will be commercially available by July 2006. Also, practices with the current Zyoptix system will be given an option to upgrade to the faster technology.
Related Videos
Related Content
